Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Formation of multimeric antibodies for self-delivery of active monomers.

Posted by on in 2017
  • Font size: Larger Smaller
  • Hits: 502
  • Print

Dekel Y1,2,3Machluf Y4Gefen T3,5Eidelshtein G6Kotlyar A6Bram Y7Shahar E3,5Reslane F3,5Aizenshtein E3,5Pitcovski J3,5. 2017. Drug Deliv. 24(1):199-208. doi: 10.1080/10717544.2016.1242179

1a Shamir Research Institute, University of Haifa , Kazrin , Israel.2b Department of Clinical Laboratory , Zefat Academic College , Zefat , Israel.3c Department of Life Sciences , Tel Hai College , Upper Galilee , Israel.4d Consultant, specialist in the fields of biochemistry, molecular biology and genetics.5e MIGAL - Galilee Technology Center , Kiryat Shmona , Israel.6f Department of Biochemistry and Molecular Biology, Tel Aviv University, Tel Aviv, Israel , and.7g Department of Molecular Microbiology and Biotechnology , Tel Aviv University , Tel Aviv , Israel.


Proteins and peptides have been used as drugs for almost a century. Technological advances in the past 30 years have enabled the production of pure, stable proteins in vast amounts. In contrast, administration of proteins based on their native active conformation (and thus necessitating the use of subcutaneous injections) has remained solely unchanged. The therapeutic anti-HER2 humanized monoclonal immunoglobulin (IgG) Trastuzumab (Herceptin) is a first line of the treatment for breast cancer. Chicken IgY is a commercially important polyclonal antibody (Ab). These Abs were examined for their ability to self-assemble and form ordered aggregates, by several biophysical methods. Atomic force microscopy analyses revealed the formation of multimeric nanostructures. The biological activity of multimeric IgG or IgY particles was retained and restored, in a dilution/time-dependent manner. IgG activity was confirmed by a binding assay using HER2 + human breast cancer cell line, SKBR3, while IgY activity was confirmed by ELISA assay using the VP2 antigen. Competition assay with native Herceptin antibodies demonstrated that the binding availability of the multimer formulation remained unaffected. Under long incubation periods, IgG multimers retained five times more activity than native IgG. In conclusion, the multimeric antibody formulations can serve as a storage depositories and sustained-release particles. These two important characteristics make this formulation promising for future novel administration protocols and altogether bring to light a different conceptual approach for the future use of therapeutic proteins as self-delivery entities rather than conjugated/encapsulated to other bio-compounds.


Protein drug release; antibodies; bioactivity; multimers; self-delivery

Last modified on